Lee Jungsoo, Kim Youngbeom, Shin Kihyuk, Kim Hoon-Soo, Ko Hyun-Chang, Kim Moon-Bum, Kim Byung-Soo
Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea.
Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.
Allergy Asthma Immunol Res. 2024 Sep;16(5):546-554. doi: 10.4168/aair.2024.16.5.546.
Prurigo nodularis (PN) is a chronic neuroinflammatory dermatosis with severe pruritus that has limited efficacy in various conventional treatments. This study investigated the outcomes of upadacitinib treatment in patients with refractory PN. A prospective study was conducted to screen for potential chronic infections prior to treatment. Upadacitinib was administered at a daily dose of 15 mg for 24 weeks, and the treatment response was assessed using the itch Numeric Rating Scale (NRS), investigator's Global Assessment (IGA), and Dermatology Life Quality Index (DLQI). Adverse events were monitored at each visit. Ten patients, with an average age of 48.8 years, were included in the study. All participants were treated with systemic cyclosporine before receiving upadacitinib, which yielded limited responses. At baseline, the mean prurigo severity scores assessed using the IGA, DLQI, and itch NRS were 3.4, 17.8, and 8.1, respectively; after 24 weeks of treatment, these scores significantly reduced to 1.0, 0.6, and 0.8, respectively. No severe adverse effects were observed. In conclusion, upadacitinib could be considered an alternative therapeutic option with good tolerability for refractory PN.
结节性痒疹（PN）是一种慢性神经炎性皮肤病，伴有严重瘙痒，各种传统治疗方法的疗效有限。本研究调查了乌帕替尼治疗难治性PN患者的疗效。在治疗前进行了一项前瞻性研究，以筛查潜在的慢性感染。乌帕替尼以每日15mg的剂量给药，持续24周，并使用瘙痒数字评定量表（NRS）、研究者整体评估（IGA）和皮肤病生活质量指数（DLQI）评估治疗反应。每次就诊时监测不良事件。10名平均年龄为48.8岁的患者纳入研究。所有参与者在接受乌帕替尼治疗前均接受过全身性环孢素治疗，但疗效有限。基线时，使用IGA、DLQI和瘙痒NRS评估的平均痒疹严重程度评分分别为3.4、17.8和8.1；治疗24周后，这些评分分别显著降至1.0、0.6和0.8。未观察到严重不良反应。总之，对于难治性PN，乌帕替尼可被视为一种耐受性良好的替代治疗选择。
